

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Roger LORIA

Application No.: 09/255,499

Filed: January 6, 1999

For: 5-ANDROSTENE-3 $\beta$ , 17 $\alpha$ -DIOL AS AN  
INHIBITOR OF TUMOR GROWTH



Group Art Unit: 1614

Examiner: J. Goldberg

RECEIVED  
MAY 28 2002  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


U.S. Patent No. 4,628,052

A fee in the amount of \$240.00 (126) is enclosed in conformance with 37 C.F.R. § 1.97(c).

To assist the Examiner, the document is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Malcolm K. McGowan, Ph.D.  
Registration No. 39,300

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: August 28, 2000